Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Novartis
Eli Lilly and Company
Tango Therapeutics, Inc.
Actuate Therapeutics Inc.
RasCal Therapeutics, Inc.
Filamon LTD
Adela, Inc
Eli Lilly and Company
Dysplasia Diagnostics Limited
Var2 Pharmaceuticals
Black Diamond Therapeutics, Inc.
Degron Therapeutics Co.
Massive Bio, Inc.
LigaChem Biosciences, Inc.
Alpha Biopharma (Jiangsu) Co., Ltd.
Incyte Corporation
Guangzhou JOYO Pharma Co., Ltd
Apollomics Inc.
Tempus AI
Blueprint Medicines Corporation
Taproot Health
Daiichi Sankyo
ABM Therapeutics Corporation
VitaMed Research LLC
Shanghai Yunying Medical Technology
Quadriga Biosciences, Inc.
Genentech, Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Novartis
SpeciCare
DEKK-TEC, Inc.
Celgene
Shenzhen BinDeBio Ltd.
BBB-Therapeutics B.V.
GE Healthcare
Angiochem Inc
Pharmacyclics LLC.
Novartis
Novartis
Pharmacyclics LLC.
Siemens Molecular Imaging
Thallion Pharmaceuticals
Copharos